Prior Postings
Press release content from Business Wire. GenSight Biologics Announces Presentation of 72-Week Data from the REVERSE Phase III Trial of GS010 at the Annual Meeting of the American Academy of Neurology (AAN)
Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, today announces the appointment of Thomas Hohman, Ph.D., an established industry leader who oversaw the development of multiple ophthalmology therapies for more than 30 years, to its Board of Directors.
Dr. Thomas Walters MD delivered a podium presentation at the annual meeting of the American Society of Cataract and Retinal Surgery (ASCRS) 2019 in San Diego updating on the progress of the NCX 470 Phase 2 clinical study in patients with glaucoma or ocular hypertension.
Doctors on a mission to eradicate preventable blindness in nine countries
Glaucoma is the leading cause of irreversible blindness and visual impairment in Nigeria — but the need for life-long treatment is putting donors off from supporting patients.
Outcome of phacoemulsification combined with excisional goniotomy using the Kahook Dual Blade in severe glaucoma patients at 6 months Matthew T Hirabayashi, Joshua T King, Dayeong Lee, Jella A An Mason Eye Institute, University of Missouri School of Medicine, Columbia, MO 65201, USA Purpose: The aim of this study was to describe 6-month rates of achieving target IOP without requiring additional glaucoma surgery after excisional goniotomy using the Kahook Dual Blade combined with phacoemulsification (phaco-KDB) in patients with severe-stage glaucoma.Methods: Retrospective review of 42 eyes from 36 patients with severe glaucoma who received phaco-KDB. Primary and secondary open-angle and combined-mechanism glaucoma were included. Preoperative, intraoperative, and postoperative data were collected through the 6-month follow-up period. The primary outcome was proportion of patients achieving IOP ≤15 mmHg without additional glaucoma procedures. Secondary outcomes were mean change in IOP, reduction of glaucoma medications, additional glaucoma procedures needed, and adverse events.Results: Preoperative baseline mean IOP was 17.1±4.8 mmHg (mean ± SD) and number of medications was 2.4±1.3. At 6 months, 64.3% (27/42) of eyes had achieved IOP ≤15 mmHg without additional glaucoma procedures, 45.2% (19/42) reached this target IOP on fewer medications, and 31.0% (13/42) on no medications. Mean IOP reduction was 2.1±4.67 mmHg (P=0.022) and mean medication reduction was 1.2±1.4 (P≤0.001). Visually significant complications were experienced by 7.1% (3/42) of eyes, and 7.1% (3/42) required additional IOP-lowering procedures within 6 months of surgery.Conclusion: Patients with severe-stage open-angle glaucoma achieved significant IOP and medication reductions following phaco-KDB. Notably, about two-thirds of eyes achieved an IOP of ≤15 mmHg at 6 months without additional glaucoma procedures. Complications and need for additional procedures were rare. Phaco-KDB may be an effective and safe alternative to more invasive filtering surgery in many patients with severe glaucoma. Keywords: glaucoma, goniotomy, IOP
WHO estimates that in 2010 there were 285 million people visually impaired, of which 39 million were blind This new research will enable the creation of new, better, treatments against a number of sight-threatening diseases The team’s research may also help to devise new strategies to mend hearts after a heart attack.
Now that Alcon is officially off on its own, what is Novartis and its remaining eye medicine business looking at next? Cutting-edge innovations, including gene therapies and digital therapeutics, the franchise's top executive said in an interview—and maybe some dealmaking, too.
Eye injuries in a deployed setting can be a significant setback for any Airman, but new telemedicine capabilities are helping to keep them in the fight. With funding from the 59th Medical Wing, Joint
Womack Army Medical Center’s Ophthalmology Clinic has expanded its services to support a collaborative initiative that serves the Fort Bragg community.